Cannabis Business Times' Best Cannabis Companies to Work For - 2027 Is Accepting Entries! Enter now.

Cannabis Business Times' Best Cannabis Companies to Work For - 2027 Is Accepting Entries! Enter now.

9 Tips for Getting Your Business Cash-Positive in 2023 | Cannabis Business Times

Continue to Site »
Site will load in 15 seconds

Continue to Site »X

9 Tips for Getting Your Business Cash-Positive in 2023

At Cannabis Conference 2022, Colin Kelley, operating partner for private equity fund Merida Capital Holdings, moderated an open dialogue with three seasoned cannabis operators to gather insights on how they've avoided–and learned from—common, costly missteps and built a profitable business.

Untitled Design 2023 01 23t145956 311

Las Vegas Event Photography

Andriana Ruscitto

January 24, 2023

Starting a business can be challenging, especially in the legal cannabis space, where rules and regulations change often and vary from state to state.

Log in to view the full article

8th Annual ‘Best Cannabis Companies to Work For’ Now Open for Entries

Closing the Hemp Loophole Does Not Mean Your Business Has to Close (Opinion)

Cannabis Workforce Solutions: How Licensed Cultivators, Dispensaries Benefit From Industry-Education Alliances (Opinion)

The Race to Nowhere: How Chasing Potency Undermines Cannabis Quality (Opinion)

The Biggest Things About Schedule III You Haven’t Thought Of

Brian Vicente of Vicente LLP talks Schedule III with Cannabis Business Times

America Mj 679861553

Closing the Hemp Loophole Does Not Mean Your Business Has to Close (Opinion)

Potential changes to the 2018 Farm Bill’s definition of hemp, if enacted, mean businesses will have one year to adapt their operations.

Seth Goldberg Opinion

Cannabis Workforce Solutions: How Licensed Cultivators, Dispensaries Benefit From Industry-Education Alliances (Opinion)

As the cannabis industry matures, the integration of targeted workforce and business development training will be essential.

Vee Display Pexels Mikhail Nilov 9159037

The Race to Nowhere: How Chasing Potency Undermines Cannabis Quality (Opinion)

The current THC labeling system is misleading, and consumers deserve more accurate, meaningful information.

Orville Bovenschen Village Farms Canadian Cannabis Top Story Image

German Cannabis Market Establishes Foundation for Global Industry Expansion (Op-Ed)

The fact that legal cannabis in Germany is more affordable than the illegal market is revolutionary for the global cannabis industry to date.

Germany Graphic

Innovating for the Benefit of Patients in Medical Cannabis (Opinion)

Poor bioavailability formulations in orally delivered medical cannabis have left an innovation gap for patients.

Stenocare 365250395

Rescheduling Update: How Long Is the Wait? What’s Next?

Government affairs and policy expert David Mangone tells us what we can expect from the DEA as weeks pass following the public comment period, including insights on the DEA’s final review and if a hearing is likely to be granted.

David Mangone Interview Top Story Image

Mitch Meyers on How to 'Manage the Chaos' in Cannabis

The founder of Missouri's BeLeaf Medical says women are 'uniquely suited' to be leaders in the male-dominated industry.

Mitch Meyers, founder, BeLeaf Medical

7 Takeaways From the Feds' Cannabis Rescheduling Recommendation

Attorney Jonathan Havens outlines what stood out for him most after reviewing the 252-page document released by the U.S. Department of Health & Human Services.

Opinion Top Story Havens 948x514

Opinion: The Cannabis Industry Must Prioritize Worker Safety, Invest in PPE

The hazards associated with cannabis production are well-documented, and it's time for the industry to step up and prioritize the health and safety of its employees.

Opinion Top Story Roggen 948x514

Federal Government Continues to Withhold Key Cannabis Scheduling Recommendation Letter Despite FOIA Requests, Lawsuit

After nearly three months and multiple Freedom of Information Act requests, the U.S. Department of Health and Human Services still has not publicly confirmed that it recommended cannabis be reclassified as a Schedule III controlled substance. One attorney who filed a lawsuit to obtain the letter calls the situation "asinine" and "profoundly disappointing."

A screenshot of the redacted letter from the U.S. Department of Health and Human Services Cannabis Business Times received in response to its Freedom of Information Act Request.

A Positive Sign For Schedule III

In Vienna, a U.S. state department legal adviser champions member-state discretion over domestic drug policy, potentially removing the obstacle the Single Convention drug treaty could pose to cannabis reform.

Opinion Top Story Pennington

Page 1 of 51